@article{3087637,
    title = "Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized phase III aurelia trial",
    author = "Poveda, A.M. and Selle, F. and Hilpert, F. and Reuss, A. and Savarese, A. and Vergote, I. and Witteveen, P. and Bamias, A. and Scotto, N. and Mitchell, L. and Pujade-Lauraine, E.",
    journal = "Journal of Clinical Oncology",
    year = "2015",
    volume = "33",
    number = "32",
    pages = "3836-3838",
    publisher = "American Society of Clinical Oncology",
    issn = "0732-183X, 1527-7755",
    doi = "10.1200/JCO.2015.63.1408",
    keywords = "bevacizumab;  doxorubicin;  paclitaxel;  topotecan;  antineoplastic agent;  bevacizumab;  doxorubicin;  macrogol derivative;  paclitaxel;  platinum derivative;  topotecan, adult;  aged;  cancer combination chemotherapy;  cancer diagnosis;  cancer recurrence;  cancer resistance;  controlled study;  female;  human;  intention to treat analysis;  Letter;  major clinical study;  open study;  outcome assessment;  ovary cancer;  overall survival;  phase 3 clinical trial;  platinum resistant recurrent ovarian cancer;  priority journal;  progression free survival;  quality of life;  randomized controlled trial;  analogs and derivatives;  cancer grading;  cancer staging;  clinical trial;  drug administration;  drug resistance;  Kaplan Meier method;  middle aged;  Ovarian Neoplasms;  pathology;  prognosis;  risk factor;  treatment outcome;  tumor recurrence;  very elderly, Adult;  Aged;  Aged, 80 and over;  Antineoplastic Combined Chemotherapy Protocols;  Bevacizumab;  Doxorubicin;  Drug Administration Schedule;  Drug Resistance, Neoplasm;  Female;  Humans;  Kaplan-Meier Estimate;  Middle Aged;  Neoplasm Grading;  Neoplasm Recurrence, Local;  Neoplasm Staging;  Ovarian Neoplasms;  Paclitaxel;  Platinum Compounds;  Polyethylene Glycols;  Prognosis;  Risk Factors;  Topotecan;  Treatment Outcome"
}